Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2011

Notch1 loss of heterozygosity causes vascular tumors and lethal
hemorrhage in mice
Zhenyi Liu
Washington University School of Medicine in St. Louis

Ahu Turkoz
Washington University School of Medicine in St. Louis

Erin N. Jackson
Washington University School of Medicine in St. Louis

Joseph C. Corbo
Washington University School of Medicine in St. Louis

John A. Engelbach
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Liu, Zhenyi; Turkoz, Ahu; Jackson, Erin N.; Corbo, Joseph C.; Engelbach, John A.; Garbow, Joel R.; PiwnicaWorms, David R.; and Kopan, Raphael, ,"Notch1 loss of heterozygosity causes vascular tumors and lethal
hemorrhage in mice." The Journal of Clinical Investigation. 121,2. 800-808. (2011).
https://digitalcommons.wustl.edu/open_access_pubs/1672

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Zhenyi Liu, Ahu Turkoz, Erin N. Jackson, Joseph C. Corbo, John A. Engelbach, Joel R. Garbow, David R.
Piwnica-Worms, and Raphael Kopan

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/1672

Downloaded on October 2, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/43114

Research article

Related Commentary, page 508

Notch1 loss of heterozygosity
causes vascular tumors and lethal
hemorrhage in mice
Zhenyi Liu,1 Ahu Turkoz,1 Erin N. Jackson,1,2,3 Joseph C. Corbo,4 John A. Engelbach,5
Joel R. Garbow,5 David R. Piwnica-Worms,1,2,3 and Raphael Kopan1,3,6
1Department

of Developmental Biology, 2Molecular Imaging Center, Mallinckrodt Institute of Radiology, 3BRIGHT Institute,
of Pathology and Immunology, 5Biomedical MR Laboratory, Department of Radiology, and 6Division of Dermatology,
Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

4Department

The role of the Notch signaling pathway in tumor development is complex, with Notch1 functioning either
as an oncogene or as a tumor suppressor in a context-dependent manner. To further define the role of
Notch1 in tumor development, we systematically surveyed for tumor suppressor activity of Notch1 in vivo. We
combined the previously described Notch1 intramembrane proteolysis–Cre (Nip1::Cre) allele with a floxed
Notch1 allele to create a mouse model for sporadic, low-frequency loss of Notch1 heterozygosity. Through
this approach, we determined the cell types most affected by Notch1 loss. We report that the loss of Notch1
caused widespread vascular tumors and organism lethality secondary to massive hemorrhage. These findings reflected a cell-autonomous role for Notch1 in suppressing neoplasia in the vascular system and provide
a model by which to explore the mechanism of neoplastic transformation of endothelial cells. Importantly,
these results raise concerns regarding the safety of chronic application of drugs targeting the Notch pathway, specifically those targeting Notch1, because of mechanism-based toxicity in the endothelium. Our strategy also can be broadly applied to induce sporadic in vivo loss of heterozygosity of any conditional alleles in
progenitors that experience Notch1 activation.
Introduction
The Notch pathway is an evolutionarily conserved signaling mechanism that plays essential roles both during development and in
the maintenance of adult tissue homeostasis in metazoan (1).
Activation of Notch receptors involves the sequential cleavage by
ADAM10 and γ-secretase, which results in the release of the Notch
intracellular domain (NICD). NICD translocates into the nucleus,
where it binds RBPJK and recruits Mastermind and coactivators
to turn on target gene expression (Figure 1A and ref. 1). The physiological outcome is highly context dependent: Notch1 can promote differentiation in some tissues while acting to maintain stem
cell proliferation in others. Consequently, Notch1 can act either as
a tumor suppresser or as an oncogene (2). In contrast to gain-offunction mutations in Notch1 and their oncogenic role in T-ALL
(3, 4), and perhaps in solid tumors, Notch1 loss-of-function mutations have only been implicated in a limited number of tumors,
such as skin (2), where Notch1 loss promotes tumor formation
non–cell-autonomously by creating a wound-like environment
and autonomously by enhancing progression to cancer (5, 6).
To determine whether Notch1 acts as a tumor suppressor in
additional tissues, we combined a previously reported knockin
line, NIP1::Cre allele (N1::Crelo; ref. 7), with a floxed Notch1 allele (8)
to perform an unbiased survey of cell types that will gain a growth
advantage when Notch1 is lost. We observed that mice with the
genotype of N1::Crelo/fl had a shorter median life expectancy and
developed vascular tumors in various organs, but most frequently
in the liver. Our findings are in agreement with reports suggesting that blockade of the Notch signaling pathway could enhance
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EC proliferation (9, 10) and suggest a link between loss of Notch1
signaling and formation of vascular tumors. This finding raises
concerns about Notch-targeting therapies in humans, in which
vascular tumors may arise after chronic exposure to inhibitory
Notch1 antibodies (11, 12), decoy ligands (such as Dll4; ref. 9),
anti-Dll4 antibodies (9, 10, 13), dominant-negative Mastermindlike 1 (MAML1) mimetics (14), or γ-secretase inhibitors, which are
being considered as therapeutic interventions for cancer. Moreover, our model can facilitate biomarker identification and help
uncover molecular mechanisms of vascular tumors.
Results
A model of sporadic Notch1 loss of heterozygosity. Ligand-mediated activation of Notch involves 2 sequential cleavage events that release
the NICD from the cell membrane (Figure 1A). This unique activation mechanism allowed us to generate N1::Cre knockin mice (7), in
which exons 28–31 of a Notch1 allele (N1) are replaced with cDNA
encoding the λ-phage–derived site-specific recombinase Cre and a
C-terminal 6Xmyc tag (6MT). Consequently, this is a null Notch1
allele producing a Notch1-Cre6MT fusion protein that releases
Cre6MT from the cell membrane following ligand binding and
subsequent proteolysis (Figure 1A and ref. 7). We have previously
reported that when N1::Cre is combined with the RosaLacZ reporter,
the excision of the floxed stop cassette by ligand-dependent release
of Cre indelibly labels cells that have experienced Notch1 activation. An active LacZ allele is then inherited by all their descendents,
providing a powerful tool for lineage mapping (7).
We reasoned that a combination of N1::Cre expressed from one
allele with a floxed Notch1 expressed from the other will produce
mice in which the remaining functional (floxed) Notch1 allele
would be inactivated at some frequency after every round of Notch1
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Figure 1
N1::Cre excises floxed Notch1 after activation. (A and B) Loss of functional Notch1 is a low-frequency event, since only a small number of
Cre6MT molecules reach the nucleus. C-terminal 6MT is omitted from the diagram for clarity. CoA, coactivator; CoR, corepressor; MAM, Mastermind. (C) All N1::Crelo/fl mice developed corneal plaques after 2–3 months, and this phenotype became more severe as animals aged. LacZ
staining revealed that the transparent corneal was transformed into a skin-like structure with neoangiogenesis. Not all ECs and keratinocytes
were labeled with lacZ. (D) N1::Crelo/fl mice showed increased angiogenesis in the ear. Scale bars: 150 μm (C); 10 mm (D).

activation by the N1::Cre protein. This will create progressive, agedependent Notch1 loss of heterozygosity (LOH; Figure 1B). Because
of the low expression level (Supplemental Figure 1), the fusion
with 6MT, and the inherently inefficient, ligand-dependent release
of Cre from the membrane, very few cells will lose Notch1 after
each round of Notch1 activation in this line (referred to herein as
N1::Crelo). Cells that experience multiple rounds of Notch1 activation have a higher probability of becoming Notch1 null. Whereas loss
of Notch1 may have no consequences on cells that only need 1 round
of Notch1 activation and/or in which other Notch receptors can
compensate for Notch1 loss, cells depending on Notch1 to maintain
tissue homeostasis or promote the exit from cell cycle may begin to
accumulate after Notch1 LOH. Their expansion could be detected
by 1 of 3 reporter alleles knocked into the Rosa locus downstream
of a floxed stop cassette: first, an allele containing click-beetle red
(CBR) luciferase that permits periodic noninvasive in vivo luciferase
imaging of tumor progression (RosaCBR; Supplemental Figure 2);
second, an allele harboring LacZ that allows single-cell resolution
postmortem analysis (RosaLacZ; ref. 15); third, an allele bearing
enhanced yellow fluorescent protein (EYFP) that facilitates fluorescence-activated cell sorting to purify cells that have experienced
Cre activity (RosaEYFP; ref. 16). To control for the possible contribution from the Cre protein (17) or from Notch1 heterozygosity (18, 19), we compared mutant N1::Crelo/fl mice with control
N1::Crelo/+ littermates throughout this study.

N1::Crelo/fl mice develop corneal plaques and display increased angiogenesis.
N1::Crelo/fl pups were born at the expected Mendelian ratio and were
indistinguishable from their littermate controls at weaning. In
contrast, when the floxed Notch1 allele was combined with a knockin allele with improved expression of untagged Cre (i.e., N1::Crehi),
a higher LOH frequency was observed, resulting in embryonic
lethality at E10.5 due to defective angiogenic remodeling within
the yolk sac (Supplemental Figure 1 and refs. 20, 21). Thus, the
low frequency of Notch1 LOH in N1::Crelo/fl animals better mimics
Notch1 LOH in human patients.
LOH in N1::Crelo/fl mice became evident when all animals developed corneal hyperplasia after 2–3 months (Figure 1C), as previously reported for mice with corneal Notch1 deletion (22). X-gal
staining showed that the normal transparent, avascular cornea was
replaced by a vascularized epidermis-like structure. Not all keratinocytes and ECs expressed lacZ (Figure 1C), which indicates that
Notch1 loss in a fraction of corneal epithelial cells was sufficient to
disrupt corneal differentiation.
N1::Crelo/fl mice develop vascular tumors, predominantly in the liver. The
design of our experiment permitted both control and mutant animals
to activate the CBR luciferase reporter gene by removal of a floxed stop
cassette in a Notch1 activation–dependent manner. In addition to the
corneal phenotype and to increased angiogenesis in ears (Figure 1D),
no other phenotypes were detected during monthly scans for elevated
luciferase activity (see below). However, Kaplan-Meier analysis of 45
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Figure 2
N1::Crelo/fl mice developed vascular tumors. (A) Kaplan-Meier survival analysis of 41 mutant and 45 control animals. Animals euthanized or
alive at the time of analysis were censored (44 control and 26 mutant). (B) Summary of the major pathological findings from a comprehensive
analysis of 13 pairs of control and mutant animals. Some animals developed hemangiomas in multiple tissues, making the tumor count greater
than 13. The distribution of hemangiomas in different organs is further dissected (see Supplemental Table 1). (C–F) Representative images
of spleen (C) and liver from N1::Crelo/+ (D) and N1::Crelo/fl animals (E and F). (E) Liver from a naturally deceased animal. (F) Liver from a
euthanized N1::Crelo/fl animal, in which the tumors were still intact and filled with blood. (G–I) H&E liver sections from N1::Crelo/+ (G) and N1::
Crelo/fl animals (H and I). See Results for details. (J–L) Immunostaining of liver tumor for PECAM (J), vWF (K), and PECAM and Ki67 (L). Inset
in L shows the enlarged view of boxed area. Representative vascular tumors in other organs are shown in M (skin; H&E) and N (ovary; vWF).
Scale bars: 50 μm; 10 μm (L, inset).

control and 41 mutant animals demonstrated that the mutants had
significantly reduced life expectancy compared with their littermate
controls (~420 versus ~600 days; P < 10–4, log-rank test; Figure 2A). To
investigate the underlying pathology, we performed comprehensive
802

necropsy analysis on 13 pairs of control and mutant animals. Postmortem analysis of mutant animals revealed reactive splenomegaly
(Figure 2C), characterized by marked expansion of the interfollicular
compartments with extramedullary hematopoiesis of granulocytic,
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Figure 3
Imaging tumor progression. (A) MRI was used to assess tumor progression in the liver. H&E images of the liver from respective animals are also
shown. Scale bar: 100 μm. (B) Bioluminescence imaging of live animals and freshly dissected organs at the specified ages. Shown are mean and
SD of organ luciferase signal (105 photons/s) from at least 4 different individuals of the same genotype. Organs showing statistically significant
differences in signal intensity are boxed in red. See Supplemental Figure 6 for images of more organs.

erythrocytic, and megakaryotic lineages and no bias in B/T cell lineages (Supplemental Figure 3), and consistent with the observed
inflammation in the liver (Supplemental Figure 4). The presence of
blood in the abdominal cavity (hemoperitoneum) was noted in 6 of
7 naturally deceased animals (Figure 2B). Different from control liver
(Figure 2D), the mutant liver from naturally deceased mutant mice
was often pale, with many irregular reddened foci (Figure 2E). Some
patches were almost white. Hemoperitoneum, in association with
the irregular contour of the liver lobes, indicated that these patches
might represent the collapse of blood-filled vascular spaces. Indeed,
inspection of the liver in euthanized nonmoribund mutant animals

of similar age revealed no blood in the abdominal cavity. Instead, the
liver often contained numerous reddened, large blood-filled spaces,
consistent with a diagnosis of a vascular tumor (Figure 2F).
Examination of H&E sections of mutant liver revealed various
abnormalities (Supplemental Figure 4). In 11 of 13 animals, the
normal homogenous and compact hepatic parenchyma seen in
controls (Figure 2G) was replaced either with solid, hypercellular
tissue composed of spindle and epithelioid cells interspaced with
numerous vascular channels (Figure 2H) or with irregular vascular
channels lined by cells with a scant-to-moderate eosinophilic cytoplasm and round-to-oval nuclei (Figure 2I). The nuclei in cells lin-
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Figure 4
Comparison of the RosaEYFP reporter labeling efficiency in ECs of
different organs in N1::Crelo/+RosaEYFP/LacZ mice. (A) ECs from liver,
kidney, spleen, heart, and lung were enriched, stained with CD45 and
CD31, and subjected to flow cytometry analysis. Percent CD31+EYFP–
and CD31+EYFP+ cells among CD45– cells is indicated. (B) Statistical
analysis on 4 N1::Crelo/+RosaEYFP/LacZ mice showed that the liver had
the highest percentage of EYFP+ ECs (about 20%, compared with less
than 5% in other organs). *P < 0.05.

ing vascular cavities either were hyperchromatic or contained coarse
chromatin (Figure 2I and Supplemental Figure 5). The endothelial
origin of these cells was confirmed by strong staining with EC markers PECAM-1 (CD-31) and vWF (Figure 2, J and K). Many cells were
also positive for the cell proliferation marker Ki67 (Figure 2L). These
findings were consistent with a diagnosis of vascular tumor/hemangioma in most animals, with incipient hemangiosarcoma in a few.
Although comprehensive analysis on all 13 pairs of animals
exposed a plethora of minor anatomic phenotypes and symptoms
in addition to those described above (Figure 2B), the statistically
significant finding (P = 10–5, 1-tailed Fisher exact test) was that 11
of 13 mutant animals (84.6%) had hemangioma/vascular tumors,
some with multiple involved organs. These included the ovary,
testis, skin, lymph node, uterus, and colon (Figure 2, B, M, N, and
Supplemental Table 1). Nonetheless, the liver was the primary
site affected in 81.8% of mutant animals (9 of 11; Figure 2B and
Supplemental Table 1), within which the tumor progression could
be assessed with MRI (Figure 3A and Supplemental Videos 1–3).
In contrast to mutant animals, none of the control animals developed vascular tumors (Figure 2B), even late in life (~2 years).
Incidence of vascular tumors in various organs correlates with efficiency
of EC labeling. The high incidence rate of hemangioma in the liver
prompted us to ask whether Notch1 activation is similar in all
vascular (i.e., red) organs. Flow cytometry analysis of EYFP+ ECs
from control N1::Crelo/+ animals revealed that the liver ECs had
significantly higher EYFP labeling efficiency (Figure 4), perhaps
reflecting higher remodeling rates. Interestingly, these differences
mirrored tumor incidence rates (Figure 2B).
804

Bioluminescence imaging of tumor progression. Our attempt to monitor tumor growth in mutant animals by in vivo imaging with CBR
luciferase failed, because of the overwhelmingly strong signal from
LOH of Notch1 in the intestine (Figure 3B and ref. 7). However, no
lesions were found in the intestinal system, consistent with the
redundant role for Notch2 in this niche (23). Notch2 activation
was not detected in any EC (data not shown). To confirm that vascular tumor cells experienced Cre activity, we performed ex vivo
bioluminescence imaging on freshly dissected organs and observed
statistically significant differences between control and mutant
liver starting at as early as 1 month of age, long before animal
survival was compromised (Figure 3B). Notably, bioluminescence
increased with tumor progression (Figure 3B and Supplemental
Figure 6). The failure to identify any other foci with significantly
increased bioluminescence among 12 N1::Crelo/fl animals indicates
that other tumors were unlikely to be present.
EC proliferation is a direct consequence of Notch1 loss. Histological
analysis identified multiple LacZ-positive ECs within the mutant
liver parenchyma; costaining of PECAM/Ki67, PECAM/EYFP, and
EYFP/BrdU confirmed that proliferating (Ki67+ or BrdU+) cells
were of endothelial origin, expressed the reporter, and may have
lost functional Notch1 (Figure 2L and Figure 5A).
The analyses performed thus far suggest that Notch1 deletion
occurred in many ECs in the N1::Crelo/fl animal. To evaluate the
status of the Notch1 locus in liver ECs, we enriched for these cells
by a Percoll gradient isolation (24, 25) followed by fluorescenceactivated cell sorting (FACS). CD105 +CD45– proliferating liver
ECs from N1::Crelo/flRosaEYFP/LacZ and N1::Crelo/+RosaEYFP/LacZ mice
were collected (Figure 6A), and the DNA was purified and subjected to PCR amplification in order to detect the 3 Notch1 alleles:
a normal promoter in the N1::Crelo allele, a floxed promoter in N1fl
allele, and a rearranged N1del allele lacking the proximal promoter
and exon1 (Figure 6B). In all tissues isolated from N1::Crelo/fl animals, N1del was readily detected (Figure 6B, bottom). In addition,
both the N1fl and the wild-type N1::Crelo promoters were detected
in multiple tissues and in unsorted cells (Figure 6B, top). In contrast, only the intact N1::Crelo allele, but not the N1fl allele, was
detected in purified, proliferating ECs (CD45–CD105+), regardless
of their EYFP expression status (Figure 6A, gates c and d). This
indicates that the vast majority (>90%; Supplemental Figure 7)
of proliferating liver ECs have lost the functional (N1fl) allele.
Analysis of DNA from cells sorted with the pan-EC marker CD31
detected the N1fl allele in both CD31+EYFP+ and CD31+EYFP– ECs
(Figure 6A, gates e and f). The presence of a functional Notch1 in
pan-ECs but not CD105+ proliferating ECs, the exclusive BrdU
labeling of EYFP+ ECs (but not any other linage in the liver; Figure 5A), and the presence of hyperphosphorylated retinoblastoma
protein (Rb; Figure 5, B–E) strongly argue that Notch1 suppresses
proliferation and vascular tumor formation cell autonomously, as
previously reported in cultured ECs (26, 27).
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Figure 5
Characterization of vascular tumor cells.
(A) LacZ-, PECAM/EYFP-, and BrdU/
EYFP-stained liver sections. A single,
2-hour-long pulse of BrdU labeled
5%–10% of ECs. Inset in right panel
shows the enlarged view of boxed area.
Scale bars: 50 μm; 10 μm (inset). (B–E)
Immunostaining of phospho-Rb. Phospho-Rb signal was absent in areas without
tumor (B and C); the presence of the signal (brown) is shown in D and E. Sections
were counterstained with hematoxylin.
The tumor identity in D and E was confirmed with PECAM and Ki67 costaining
in Figure 2L (adjacent sections). Boxed
regions in B and D are shown at higher
magnification in C and E, respectively.
Scale bars: 100 μm.

Discussion
The Notch signaling pathway is an essential component in a complex network that controls proper development and maintains tissue homeostasis in the adult. The embryonic lethality associated
with loss of Notch1 (28, 29) prevents a comprehensive evaluation of
its role in various organs in later embryonic stages or in the adult.
To circumvent this problem, most genetic approaches adopt transgenic or Cre-LoxP–based conditional loss-of-function strategies
(30) to express or remove a gene of interest in most or all cells within a population. An obvious limitation of these methods as models
for human cancer is that they do not mimic sporadic occurrence
of disease-causing mutations in a few tumor-initiating cells, which
later evolve into a tumor. Moreover, transgenic approaches could
overwhelm the immune system or disrupt homeostatic mechanisms that might otherwise play significant roles in determining
disease progression. To overcome these limitations, hormonecontrolled CreER — a fusion protein of Cre recombinase and the
binding domain of estrogen receptor — is often used to randomly
induce sporadic overexpression or deletion of a gene of interest.
Such strategy has been recently used to induce the sporadic expression of a SYT-SSX2 fusion gene in multiple tissues, resulting in
exclusively synovial sarcoma-like tumors (31).
Here we devised an alternative strategy to hormone-induced
CreER by taking advantage of the low-frequency, activationdependent trans-excision of a floxed Notch1 allele in N1::Crelo/fl
animals to investigate its role in the adult stage. We identified
the EC population as dependent on Notch1 activity in the adult
and defined the consequence of Notch1 loss: the development of
vascular tumors. Unlike the skin, in which tumor promotion is
elicited by the non–cell-autonomous consequences of a woundlike environment (5), the tumor suppressor function of Notch1

ECs appears to be cell autonomous. Nevertheless, although these
tumors could be found in various organs, they were most prevalent
in the liver. Consistent with this observation, we found that ECs
from liver have the highest EYFP labeling efficiency, suggestive of
higher levels of angiogenic activity and thus higher probability of
Notch1 LOH. Alternatively, some unique features of liver ECs (32),
as well as the specific anatomical or environmental factor(s), may
predispose the liver to vascular tumor formation.
Our study demonstrates the utility of NIP::Cre mice in screening
for tumor suppressor functions in vivo and indicates that NIP::Cre
mice can serve as a general model in which to initiate sporadic cancer. When compared with transgenic or regular Cre-floxed–based
strategies (30), the advantages of NIP::Cre mice are as follows: first,
the loss or gain of mutations is sporadic, and their probability can
be manipulated by selecting either the N1::Crelo or the N1::Crehi alleles
to better mimic cancer initiation in human patients; second, in gainof-function analysis, tissues that normally do not express Notch1
will not be forced to express it; third, in loss-of-function paradigms,
most cells will have an active Notch1 allele during development, and
a normal physiological niche could therefore be maintained; and
fourth, unlike a tamoxifen-dependent pulse of gene loss, cells that
continuously depend on Notch1 have a higher probability of LOH
than do cells that activate Notch1 only once in their history. Considering that Notch1 is continuously required in multiple tissues
during development and in the adult (33), especially in the gut (7,
34) and mammary gland (35) stem cell populations, a NIP::Cre allele
coupled with floxed alleles of tumor suppressors offers a better
model to mimic LOH disease development in human patients.
The Notch pathway has emerged as a target to block angiogenesis in solid tumors (9, 10, 36) and eliminate tumor-initiating cells (13), either by the administration of anti-Dll4 antibody
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Figure 6
Loss of Notch1 in ECs is associated with their
rapid expansion. (A) Liver ECs were sorted to
remove CD45 + cells and then separated based
on the expression of EYFP and either CD105
(proliferating EC marker) or CD31 (pan-EC
marker). (B) PCR analysis confirmed the deletion
of floxed Notch1 allele in the majority of CD45 –
CD105 +EYFP + and CD45 –CD105 +EYFP – cells;
in contrast, a substantial amount of floxed alleles
was still detected in CD45 – CD31 + EYFP + and
CD45 –CD31 +EYFP – cells. The primers bind at
positions illustrated in the diagram. Lanes a–f correspond with gates in A. M, molecular marker.

(9, 10, 13) or by the overexpression and/or application of a soluble Dll4 protein (9). However, here we showed that chronic reduction in Notch1 signaling could promote vascular tumor formation, and may do so in humans. Consistent with our observation,
Yan and colleagues recently showed that chronic injection of Dll4
antibodies into adult mice, rats, and monkeys induces vascular
neoplasm only in rats (37). We reproduced this observation in the
mouse using a Notch1 LOH genetic model, which indicates that
the vascular tumors found in rats treated with Dll4 antibodies
could be caused by a mechanism-based toxicity due solely to the
loss of Notch1 signaling in ECs. Concomitant loss of signals from
other Notch receptors, such as Notch4 in ECs (38) and Notch2/3
in pericytes (39–41), may have accelerated the tumor formation
in their model (37). Although no other types of tumors appear
sensitive to anti-Notch1 therapy, the therapeutic window of antiNotch therapies in general, and anti-Notch1 therapies in particular (11), needs to be carefully reevaluated.
Methods
Mice. N1::Crelo (NIP-Cre; Jax Mice strain name Notch1tm3(cre)Rko; ref. 7), Notch1
floxed conditional mice (Jax Mice strain name Notch1tm2Rko; ref. 8), and the
RosaLacZ (15) and RosaEYFP (16) reporter animals have been described
previously. N1::Crehi, an enhanced version of N1::Crelo with an increased
amount of N1::Cre fusion protein, is described previously (21, 20) and
in Supplemental Figure 1. RosaCBR, a Cre reporter line in which the gene
encoding CBR luciferase is under the control of the ubiquitous Rosa26
promoter and preceded by a floxed stop cassette, is constructed in a similar
way as the RosaLacZ (15) and RosaEYFP (16) knockin animals (Supplemental Figure 2). All animals were housed in the mouse facility of Washington
University, and all protocols were approved by the Animal Studies Committee of Washington University.
Immunohistochemistry. Paraffin sections were prepared with standard
procedures from postmortem or euthanized animals. Antigens were
retrieved by boiling at 121°C for 20 minutes in 10 mM sodium citrate buffer (pH 6.0) after deparaffinization. Endogenous peroxidase activity was
inactivated in 3% H2O2 for 15 minutes before the sections were blocked
806

with blocking buffer (3% BSA, 0.1% Tween in 1× PBS) for 1 hour at room
temperature. This was then followed by overnight incubation with different primary antibodies at 4°C. After 3 5-minute washes with 1× PBS,
sections were incubated at room temperature for 1 hour with HRP-conjugated anti-rabbit or anti-goat secondary antibodies (Vector Labs, 1:100),
depending on the host species of the primary antibodies. DAB reactions
were performed following 3 5-minute washes in 1× PBS with substrate
from Vector Labs. Sections were counterstained with hematoxylin for
30 seconds, dehydrated, and mounted with VectaMount (Vector Labs).
For immunofluorescence staining, 3% H2O2 treatment was omitted, and
DyLight488- or DyLight549-conjugated secondary antibodies (Jackson
ImmunoResearch, 1:500) were used. For frozen sections, tissues were fixed
in 4% PFA, equilibrated with 30% sucrose in 1× PBS overnight, embedded
in OCT compound, and cut at 8 μm. For BrdU staining, 10 μl 10 mg/ml 5bromo-2-deoxyuridine solution (Sigma-Aldrich) per gram body weight was
injected intraperitoneally into animals 2 hours before sacrifice. Frozen sections were first stained with chick anti-EYFP primary antibody and Alexa
Fluor 488–conjugated donkey anti-chick secondary antibody, followed by
treatment with 2N HCl at 37°C for 30 minutes and BrdU staining. The following primary antibodies were used: rabbit anti-Ki67 (Novocastra, 1:300,
paraffin sections), goat anti–PECAM-1 (M-20) (Santa Cruz, 1:50, paraffin
and frozen sections), rabbit anti-vWF (AbCam, 1:800, paraffin sections),
chick anti-GFP (Aves Lab, 1:1,000, frozen sections), rat anti-BrdU (clone
BU1/75, Accurate Chemical, 1:200, frozen sections), and rabbit anti–phospho-Rb (Ser780) (Cell Signaling, 1:100, paraffin sections).
X-gal staining. Animals were anesthetized and perfused with 2%
paraformaldehyde plus 0.25% glutaraldehyde in 1× PBS with 2 mM MgCl2.
Tissues were then dissected and postfixed in 4% paraformaldehyde in 1×
PBS with 2 mM MgCl2 on ice for 1 hour, washed, equilibrated with 30%
sucrose in 1× PBS with 2 mM MgCl2 overnight, and embedded in OCT
compound. 8-mm frozen sections were cut and stained with X-gal staining solution as described previously (7). Tissues from postmortem animals
were processed similarly, except for perfusion.
Purification of liver ECs and flow cytometry. Freshly dissected liver from control and mutant animals was mechanically disrupted between 2 glass slides
and digested with collagenase IV (Sigma-Aldrich). ECs were enriched by
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Percoll gradient centrifugation (25) and stained with PerCP-Cy5.5–conjugated anti-CD45 (BD Biosciences) and PE-conjugated anti-CD105 or
-CD31 (BioLegend) antibodies. FACS sorting was done on a MoFlo instrument (Beckman Coulter). For the comparison of EYFP labeling efficiency
in the liver, kidney, spleen, heart, and lung, tissues were first mechanically
disrupted and then digested with collagenase IV (Sigma-Aldrich, liver or
kidney, 5 mg per animal), collagenase D (Roche, lung or spleen, 5 mg per
animal), or collagenase II (Worthington, 3,000 U) supplemented with 200
U DNase I (Roche). Single-cell suspensions from peripheral blood, thymus,
spleen, and bone marrow were prepared and analyzed with flow cytometry
as described previously (42). Flow cytometry analyses were performed on
FACScan (BD Biosciences), and data were analyzed with FlowJo (Treestar).
Fluorescence-conjugated antibodies were purchased from Biolegend.
PCR. Primers 1c (5′-TGGAAGCTACTGACTTAGTAGGGGGAAAAC-3′)
and 2d (5′-GCAAGCATGAAGTGGTCCAGGGTGTGAGTG-3′) were used
for the simultaneous detection of floxed and wild-type Notch1 allele and
produced a 317-bp band for wild-type Notch1 locus and a 367-bp band for
floxed Notch1 locus. Primers 1b (5′-TGGCCTGCCTGTCTGGAACAACAGT
TCAGG-3′) and 2e (5′-ACCCTTGCCTCAGTTCAAACACAAGATACG-3′)
amplified the deleted Notch1 allele with a product size about 532 bp.
Bioluminescence imaging. For bioluminescence imaging of living animals,
mice were anesthetized with 2.5% isoflurane, injected intraperitoneally
with 150 μg/g d-luciferin (Biosynth) in PBS, and imaged with a chargecoupled device (CCD) camera–based bioluminescence imaging system
(IVIS 50, Caliper; exposure time 1–60 seconds, binning 8, field of view
12, f stop 1, open filter, anterior and posterior views). Signal was displayed as photons/s/cm2/sr (43). Regions of interest (ROIs) were defined
manually around the abdomen, throat, and whole body using Living
Image and Igor Pro Software (version 2.50), and results were analyzed
as photon flux (photons/s). Ex vivo images were obtained immediately
after live imaging. Animals were euthanized, and organs were quickly
removed and imaged for 60 seconds.
MRI. All MRI experiments were performed in Washington University’s
Biomedical MR Laboratory. Respiratory-gated, spin-echo MR images of
mice were collected with a small-animal MR scanner based on an Oxford
Instruments (Oxford) 4.7-tesla, 40-cm bore magnet. The magnet is equipped
with Magnex Scientific (Oxford) actively shielded, high-performance (21 cm
ID, ~30 G/cm, ~400 ms rise time) gradient coils and Oy International Elec1. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism.
Cell. 2009;137(2):216–233.
2. Koch U, Radtke F. Notch and cancer: a double-edged
sword. Cell Mol Life Sci. 2007;64(21):2746–2762.
3. Weng AP, et al. Activating mutations of NOTCH1
in human T cell acute lymphoblastic leukemia.
Science. 2004;306(5694):269–271.
4. Jeannet R, et al. Oncogenic activation of the Notch1
gene by deletion of its promoter in Ikaros-deficient
T-ALL [published online ahead of print September 9,
2010]. Blood. doi: 10.1182/blood-2010-05-286658.
5. Demehri S, Turkoz A, Kopan R. Epidermal Notch1
loss promotes skin tumorigenesis by impacting
the stromal microenvironment. Cancer Cell. 2009;
16(1):55–66.
6. Nicolas M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33(3):416–421.
7. Vooijs M, et al. Mapping the consequence of Notch1
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tric Company power supplies and is interfaced with a Varian NMR Systems
DirectDrive console. All data were collected using a Stark Contrast 2.5-cm
birdcage-style radio frequency coil. Prior to the imaging experiments, mice
were anesthetized with isoflurane and were maintained on isoflurane/O2
(1%–1.25% v/v) throughout data collection. Animal core body temperature
was maintained at 37°C ± 1°C by circulation of warm air through the bore
of the magnet. During the imaging experiments, the respiration rates for
all mice were regular and approximately 2 s–1. Synchronization of MR data
collection with animal respiration was achieved with a home-built respiratory-gating unit (44), and all images were collected during postexpiratory
periods. 24–30 contiguous coronal slices, ventral to dorsal, were collected
for each mouse. Imaging parameters were as follows: excitation pulse repetition time, approximately 3 s; time to echo, 30 ms; field of view, 2.5 cm2; slice
thickness, 1.0 mm; data matrix, 128 × 128; 4 averages.
Statistics. Kaplan-Meier survival analysis was done with SPSS. Unpaired
2-tailed Student’s t test was performed using Excel 2008 software.
1-tailed Fisher’s exact test was computed with Statistics Calculators
(http://www.danielsoper.com/statcalc/calc29.aspx). A P value of 0.05 or
less was considered significant.
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